Literature DB >> 23210578

Variant treatment for gastric varices with polidocanol foam using balloon-occluded retrograde transvenous obliteration: a pilot study.

Warren Clements1, Karda Cavanagh, Faizal Ali, Helen Kavnoudias, William Kemp, Stuart Roberts, Stuart Lyon.   

Abstract

INTRODUCTION: Treatment of gastric variceal rupture remains difficult with current options including transjugular intrahepatic portosystemic shunt and endoscopic therapies having significant side effects or reduced efficacy. We report five cases of gastric varices that were successfully treated with balloon-occluded retrograde transvenous obliteration of varices (BRTO) using Polidocanol foam as an alternative sclerosant to ethanolamine oleate.
METHODS: Patients were recruited with cirrhotic liver disease, a history of upper gastrointestinal bleeding, and large gastric fundal varices confirmed on gastroscopy and CT venogram. BRTO was performed as a same-day procedure using a balloon catheter inserted via a gastro-renal shunt with Polidocanol foam injected and a balloon inflated for 2 h. Follow-up was with repeat CT portovenogram, gastroscopy at 6 weeks post-procedure, and in a gastroenterology liver clinic at 1- to 3-month intervals.
RESULTS: Between January and December 2009, five patients safely underwent BRTO therapy of gastric varices without complication. At 6 weeks following the procedure, upper gastrointestinal endoscopy showed complete resolution of varices in 5 out of 5 patients, while CT portovenography showed resolution of varices in 4 out of 5 patients, with results in the last patient inconclusive. Clinical follow-up at 1, 3 and 6 months indicated no further episodes of bleeding.
CONCLUSIONS: Our study further supports the use of foam sclerosants including Polidocanol in BRTO, showing it is a safe and effective minimally-invasive procedure to treat gastric fundal varices in the short term.
© 2012 The Authors. Journal of Medical Imaging and Radiation Oncology © 2012 The Royal Australian and New Zealand College of Radiologists.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23210578     DOI: 10.1111/j.1754-9485.2012.02453.x

Source DB:  PubMed          Journal:  J Med Imaging Radiat Oncol        ISSN: 1754-9477            Impact factor:   1.735


  6 in total

1.  Response to Yang et al.

Authors:  Edward Wolfgang Lee; Stephen T Kee
Journal:  Am J Gastroenterol       Date:  2018-10-25       Impact factor: 10.864

2.  Foam Sclerotherapy during Shunt Surgery for Portal Hypertension and Varices.

Authors:  Zhe Zhang; Xueming Chen; Chenyu Li; Hai Feng; Hongzhi Yu; Renming Zhu; Tianyou Wang
Journal:  Open Med (Wars)       Date:  2017-11-22

3.  Efficacy and Safety of Ultrasound-Guided Percutaneous Polidocanol Sclerotherapy in Benign Cystic Thyroid Nodules: Preliminary Results.

Authors:  Xiaohua Gong; Qi Zhou; Fang Wang; Wenjun Wu; Xiaojun Chen
Journal:  Int J Endocrinol       Date:  2017-05-31       Impact factor: 3.257

4.  Endoscopic treatment or balloon-occluded retrograde transvenous obliteration is safe for patients with esophageal/gastric varices in Child-Pugh class C end-stage liver cirrhosis.

Authors:  Keiji Yokoyama; Ryo Yamauchi; Kumiko Shibata; Hiromi Fukuda; Hideo Kunimoto; Kazuhide Takata; Takashi Tanaka; Shinjiro Inomata; Daisuke Morihara; Yasuaki Takeyama; Satoshi Shakado; Shotaro Sakisaka
Journal:  Clin Mol Hepatol       Date:  2018-11-09

5.  Balloon-Assisted Percutaneous Transhepatic Antegrade Embolization with 2-Octyl Cyanoacrylate for the Treatment of Isolated Gastric Varices with Large Gastrorenal Shunts.

Authors:  Guangchuan Wang; Dongxiao Meng; Guangjun Huang; Qingshan Pei; Lianhui Zhao; Yongjun Shi; Mingyan Zhang; Hua Feng; Junyong Zhang; Chunqing Zhang
Journal:  Biomed Res Int       Date:  2019-04-03       Impact factor: 3.411

6.  Safety and Efficacy of a Novel Shunt Surgery Combined with Foam Sclerotherapy of Varices for Prehepatic Portal Hypertension: A Pilot Study.

Authors:  Zhe Zhang; Xueming Chen; Chenyu Li; Hai Feng; Hongzhi Yu; Renming Zhu; Tianyou Wang
Journal:  Clinics (Sao Paulo)       Date:  2019-08-19       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.